产品
编 号：F202146
分子式：C267H402N64O76S6
分子式：C267H402N64O76S6
产品类型
规格
价格
是否有货
100U
询价
询价
300U
询价
询价
结构图
CAS No: 169148-63-4
产品详情
生物活性：
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.
体内研究：
Insulin Detemir (d-INS) (5 IU/kg; i.p.; once daily; 2 weeks) demonstrates weight-sparing effects compared with other insulin formulations, and shows a intestinal tissues preference, potentially involving the activation of insulin/-catenin/CREB signaling pathways.Animal Model:Obese type 2 diabetic db/db mice
Dosage:5 IU/kg
Administration:Intraperitoneal injection; once daily for 2 weeks
Result:Decreased body weight of the mice after 14-day daily injection of d-INS (5 IU/kg) significantly compared with those injected with the same dose of human Insulin or saline.Induced rapid phosphorylation of protein kinase B (Akt) in the gut L cells of normal mice.
体外研究：
Insulin Detemir (d-INS) (100 nM; 0.5-4 h) increases Gcg mRNA expression in primary fetal rat intestinal cell (FRIC) cultures, and (100 nM; 5 min and 10 min) induces rapid phosphorylation of Akt, as well.Insulin Detemir (100 nM; 5-120 min) increases β-catenin phosphorylation, its nuclear translocation, and enhances cAMP response element-binding protein (CREB) phosphorylation in a phosphatidylinositol 3-kinase and/or mitogen-activated protein kinase kinase/extracellular signal-regulated kinase-sensitive manner.
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research.
体内研究：
Insulin Detemir (d-INS) (5 IU/kg; i.p.; once daily; 2 weeks) demonstrates weight-sparing effects compared with other insulin formulations, and shows a intestinal tissues preference, potentially involving the activation of insulin/-catenin/CREB signaling pathways.Animal Model:Obese type 2 diabetic db/db mice
Dosage:5 IU/kg
Administration:Intraperitoneal injection; once daily for 2 weeks
Result:Decreased body weight of the mice after 14-day daily injection of d-INS (5 IU/kg) significantly compared with those injected with the same dose of human Insulin or saline.Induced rapid phosphorylation of protein kinase B (Akt) in the gut L cells of normal mice.
体外研究：
Insulin Detemir (d-INS) (100 nM; 0.5-4 h) increases Gcg mRNA expression in primary fetal rat intestinal cell (FRIC) cultures, and (100 nM; 5 min and 10 min) induces rapid phosphorylation of Akt, as well.Insulin Detemir (100 nM; 5-120 min) increases β-catenin phosphorylation, its nuclear translocation, and enhances cAMP response element-binding protein (CREB) phosphorylation in a phosphatidylinositol 3-kinase and/or mitogen-activated protein kinase kinase/extracellular signal-regulated kinase-sensitive manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备